Clinical trials: Stage II Skin Cancer
Intraocular Melanoma, Malignant Conjunctival Neoplasm
Vaccine Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Vaccine therapy may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized clinical trial is studying how well vaccine therapy works in treating patients with advanced melanoma.
- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Trial name
- Mel48 (NCT00705640)
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Craig L Slingluff, Jr
Breast Cancer
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor…
- Trial name
- NCT00010140
- Testing
- docetaxel, epirubicin hydrochloride, tamoxifen citrate
- Where
- United Kingdom
- Sponsor
- International Collaborative Cancer Group
Melanoma Stage Iv, Melanoma Stage Iii
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
The purpose of this project is to test the addition of a new treatment called denosumab to standard immunotherapies for patients with metastatic melanoma.
- Conditions
- Melanoma Stage Iv, Melanoma Stage Iii, Melanoma
- Trial name
- CHARLI (NCT03161756)
- Testing
- Denosumab, Nivolumab, Ipilimumab
- Where
- 10 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Breast Cancer Stage IV
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
Datopotamab-deruxtecan in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases.
- Trial name
- TUXEDO-2 (NCT05866432)
- Testing
- Datopotamab deruxtecan
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Medical University of Vienna
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any remaining tumor cells following…
- Trial name
- NCT00047099
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 446 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Breast Cancer
Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00852332
- Testing
- Curcumin, Taxotere
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Breast Cancer
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
This is a multicenter run-in phase Ib / roll-over phase II study of triple targeted drug combination (HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib and aromatase inhibitor letrozole) as a first or…
- Trial name
- NCT03054363
- Testing
- Tucatinib in Combination with Palbociclib and Letrozole
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Colorado, Denver
Metastatic Breast Cancer
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Primary Objectives Assess ultrastructure changes in dermal myelinated nerves of patients who receive ixabepilone chemotherapy Detailed characterization of peripheral neuropathy in patients who receive ixabepilone Secondary…
- Trial name
- NCT00627978
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Cancer
Lapatinib in Combination With Vinorelbine
This is a Multicenter, Open-Label, Phase II Study of lapatinib in Combination with Vinorelbine in women with documented evidence of HER2/neu positive breast cancer which is metastatic or recurrent and with or without prior…
- Trial name
- NCT01128543
- Testing
- lapatinib and Vinorelbine
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
To evaluate the efficacy and safety of Culmerciclib combined with fulvestrant compared with investigator-selected CDK4/6 inhibitors combined with fulvestrant in patients with HR-positive/HER2-negative breast cancer who have…
- Trial name
- NCT07666555
- Testing
- CDK4/6 inhibitor, Culmerciclib, Fulvestrant
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Fudan University
Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7
Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer
This study tests four different methods of educating patients about follow-up care (NCI facing forward, brochure, EXCELS website alone, EXCELS health coaching alone and EXCELS website \& health coaching combination) after cancer…
- Conditions
- Stage I Breast Cancer, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Prostate Cancer, Stage IA Breast Cancer
- Trial name
- NCT03233555
- Testing
- Informational Intervention, Internet-Based Intervention, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 535 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer, Triple Negative Breast Neoplasms
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after…
- Trial name
- BreastImmune03 (NCT03818685)
- Testing
- Nivolumab, Ipilimumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Leon Berard
Breast Cancer
Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00674414
- Testing
- trastuzumab, everolimus, therapeutic conventional surgery
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- UNICANCER
Breast Cancer, Adenocarcinoma
Study of MDX-010 in Stage IV Breast Cancer
This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy.
- Trial name
- NCT00083278
- Testing
- MDX-010
- Where
- 14 sites in United States
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
CTIT-Chemotherapy Induced Thrombocytopenia, Breast Cancer
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study
The title of this study is: A two-cohort, single-arm, exploratory Phase II clinical study on the primary/secondary prevention ADC drug of heltrombopag for thrombocytopenia caused by breast cancer.
- Trial name
- NCT07243418
- Testing
- herombopag olamine tablets
- Volunteers
- 72 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Melanoma, Cutaneous Melanoma
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma.
- Trial name
- NCT00679289
- Testing
- HDI, KW2871
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Ludwig Institute for Cancer Research
Male Breast Cancer, Hormone Receptor-positive Breast Cancer
ETHAN - ET for Male BC
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer.
- Conditions
- Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
- Trial name
- NCT05501704
- Testing
- Tamoxifen, Anastrozole, Degarelix
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jose Pablo Leone
Breast Cancer, Triple Negative Breast Cancer
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
The study has a phase Ib and a phase II part. The phase Ib aims to evaluate the safety and tolerability of durvalumab in combination with a dose- dense EC regimen in a neoadjuvant setting for early breast cancer.
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Luminal B
- Trial name
- B-IMMUNE (NCT03356860)
- Testing
- Paclitaxel, Epirubicin, Cyclophosphamide
- Where
- 4 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Grand Hôpital de Charleroi
Breast Cancer
Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant chemotherapy in locally advanced breast cancer.
- Trial name
- NCT00191789
- Testing
- gemcitabine, doxorubicin, cisplatin
- Where
- 3 sites in India
- Volunteers
- 65 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.